Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-17-030899
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-05-09 15:37:00
Reporting Period:
2017-05-09
Filing Date:
2017-05-09
Accepted Time:
2017-05-09 15:37:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510580 Kite Pharma Inc. KITE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1296549 Arie Belldegrun C/o Kite Pharma, Inc.
2225 Colorado Avenue
Santa Monica CA 90404
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-05-09 17,000 $68.57 85,507 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,607,750 Indirect See footnote
Common Stock 159,329 Indirect See footnote
Common Stock 430,190 Indirect See footnote
Common Stock 500,000 Indirect See footnote
Common Stock 500,000 Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.45 to $68.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  2. The securities are held in the name of Arie and Rebecka Belldegrun as Trustees of the Belldegrun Family Trust dated February 18, 1994.
  3. The securities are held in the name of The Arie Belldegrun MD, Inc. Profit Sharing Plan, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. The securities are held in the name of MDRB Partnership, L.P., of which the reporting person is a managing partner. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  5. The securities are held in the name of Bioeast, LLC, of which the reporting person is a managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  6. The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the Manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.